Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study by Andreas K. Øvlisen, Anders Oest,

Slides:

Advertisements

Similar presentations

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Advertisements

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Gupta V, Tallman MS, Weisdorf DJ

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

Acute promyelocytic leukemia, microgranular variant

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Role of primacy of birth in HLA-identical sibling transplantation

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith,

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis by Julie Støve Bødker, Rasmus Froberg Brøndum,

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse by Alexander Höllein, Manja Meggendorfer, Frank Dicker,

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,

Kaplan-Meier curves for overall survival (OS) probability.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Overall survival by SCT versus observation in first complete remission

Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen,

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia by Thai Hoa Tran, Marian.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 by Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri,

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

by Christine L. Kempton, and Amanda B. Payne

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Ontogeny of platelet function

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML by Renato Bassan, Tamara Intermesoli, Arianna.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Impact of age on clinical risk scores in follicular lymphoma

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment by Waleed Ghanima, Bertrand Godeau,

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Cold agglutinin disease

Outcomes in patients with PTCL

Presentation transcript:

Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study by Andreas K. Øvlisen, Anders Oest, Mette D. Bendtsen, John Bæch, Preben Johansen, Line S. Lynggaard, Ingolf Mølle, Thomas B. Mortensen, Duruta Weber, Gideon Ertner, Claudia Schöllkopf, Jesper Q. Thomassen, Ove Juul Nielsen, Lene Sofie Granfeldt Østgård, Martin Bøgsted, Karen Dybkær, Hans E. Johnsen, and Marianne T. Severinsen BloodAdv Volume 2(5):559-564 March 13, 2018 © 2018 by The American Society of Hematology

Andreas K. Øvlisen et al. Blood Adv 2018;2:559-564 © 2018 by The American Society of Hematology

The patient cohort and defined study population. The patient cohort and defined study population. Flowchart describing the postinduction, classical CR cohort and final study population. In total, 832 patients met all inclusion criteria. Because of missing data regarding blood samples in LABKA and patients’ transfusion history, the final study population included 769 patients who were included in the population analyzed in the present study. APL, acute promyelocytic leukemia. Andreas K. Øvlisen et al. Blood Adv 2018;2:559-564 © 2018 by The American Society of Hematology

Absolute and relative numbers of patients with insufficient 3-lineage recovery. Absolute and relative numbers of patients with insufficient 3-lineage recovery. Venn diagram illustrating analysis of international consensus criteria for CR in patients who did not fulfill sCR criteria (non-sCR patients). Andreas K. Øvlisen et al. Blood Adv 2018;2:559-564 © 2018 by The American Society of Hematology

OS and RFS. Kaplan-Meier estimates for OS (A) and RFS (B) presented with 95% CIs and log-rank test for 769 patients at risk. OS and RFS. Kaplan-Meier estimates for OS (A) and RFS (B) presented with 95% CIs and log-rank test for 769 patients at risk. (A) Probability of OS in patients who achieved sCR or non-sCR. (B) Probability of RFS of patients who achieved sCR or non-sCR. Andreas K. Øvlisen et al. Blood Adv 2018;2:559-564 © 2018 by The American Society of Hematology